Lopes RD, Hong H, Harskamp RE, et al. - To define the optimal treatment for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), researchers performed this up-to-date network meta-analysis wherein they assessed the safety as well as efficacy of 4 antithrombotic regimens. They explored MEDLINE and selected 5 randomized studies. Overall 11,532 participants were analyzed. The four regimens tested were: vitamin K antagonists (VKA) plus dual antiplatelet therapy (DAPT) (reference), VKA plus P2Y₁₂ inhibitor, non-VKA oral anticoagulant (NOAC) plus DAPT, NOAC plus P2Y₁₂ inhibitor. Based on the findings, experts suggested to generally avoid an antithrombotic regimen of VKA plus DAPT, as regimens in which aspirin is discontinued may result in reduced bleeding risk and no difference in antithrombotic effectiveness. For the majority of the patients with AF undergoing PCI, the most favorable management choice and the preferred antithrombotic regimen may be a NOAC plus a P2Y₁₂ inhibitor without aspirin.